


## L-Aspartic acid disodium

<b>Cat. No.:</b>	HY-N0666D		
<b>CAS No.:</b>	5598-53-8		
<b>Molecular Formula:</b>	C <sub>4</sub> H <sub>5</sub> NNa <sub>2</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	177.07		
<b>Target:</b>	Endogenous Metabolite		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 50 mg/mL (282.37 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	5.6475 mL	28.2374 mL	56.4748 mL
	5 mM	1.1295 mL	5.6475 mL	11.2950 mL
	10 mM	0.5647 mL	2.8237 mL	5.6475 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

L-Aspartic acid disodium is an amino acid, can be used as a suitable proagent for colon-specific agent delivery<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

Microbial Metabolite

Human Endogenous Metabolite

### CUSTOMER VALIDATION

- Nat Protoc. 2021 Jan;16(1):431-457.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

---

[1]. Hosoya K, et al. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem. 1999 Sep;73(3):1206-11.

[2]. Leopold CS, et al. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm. 1995 Aug;23(4):397-406.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA